-
公开(公告)号：US08969027B2
公开(公告)日：2015-03-03
申请号：US12920771
申请日：2009-03-03
Applicant: Stefan H. Bossmann , Deryl L. Troyer , Matthew T. Basel
Inventor： Stefan H. Bossmann , Deryl L. Troyer , Matthew T. Basel
IPC: C12Q1/37 , C12N11/06 , A61K49/14 , C12N11/00 , C12N11/14 , A61K49/00 , B82Y15/00 , C07K5/113 , C07K7/06 , C07K7/08 , G01N33/58 , C12N11/02 , C12N11/04
CPC classification number: A61K49/0067 , A61K49/0036 , A61K49/0056 , A61K49/0065 , A61K49/0093 , B82Y15/00 , C07K5/1021 , C07K7/06 , C07K7/08 , C12Q1/37 , G01N33/588 , G01N2800/7028 , Y10S977/773 , Y10S977/774 , Y10S977/92
Abstract: The present invention provides a diagnostic reagent or assay for assessing the activity of a protease in vivo or in vitro and methods of detecting the presence of a cancerous or precancerous cell. The assays are comprised of two particles linked via an oligopeptide linkage that comprises a consensus sequence specific for the target protease. Cleavage of the sequence by the target protease can be detected visually or using various sensors, and the diagnostic results can be correlated with cancer prognosis.
Abstract translation: 本发明提供用于评估蛋白酶在体内或体外的活性的诊断试剂或测定法，以及检测癌性或癌前细胞的存在的方法。 测定由通过寡肽连接的两个颗粒组成，其包含对靶蛋白酶特异性的共有序列。 可以目测或使用各种传感器检测靶蛋白酶序列的切割，诊断结果可与癌症预后相关。
-
2.发明申请RENILLA/GAUSSIA TRANSFECTED CELLS AS A LIGHT SOURCE FOR IN-SITU PHOTODYNAMIC THERAPY OF CANCER 审中-公开RENILLA / GAUSSIA转染细胞作为癌症原位光化疗治疗的光源公开(公告)号：US20130243741A1
公开(公告)日：2013-09-19
申请号：US13821516
申请日：2011-09-19
Applicant: Stefan H. Bossmann , Deryl L. Troyer , Matthew T. Basel , Tej B. Shrestha , Hongwang Wang
Inventor： Stefan H. Bossmann , Deryl L. Troyer , Matthew T. Basel , Tej B. Shrestha , Hongwang Wang
IPC: A61K41/00
CPC classification number: A61K41/0057 , A61K41/0061 , A61K45/06 , A61K47/6951 , A61K48/005 , A61N5/062 , A61N2005/0653 , A61N2005/0656 , B82Y5/00 , C08B37/0015 , C08L5/16
Abstract: A method for photodynamic therapy treatment of cancerous cells and tissue is provided. The method comprises administering tumor-trophic cells expressing a luminescent protein to a subject. A photosensitizing agent is then separately administered to the subject, followed by an optional iron chelator. On the day of treatment, a luminogenic substrate corresponding to the luminescent protein is administered to the subject. The substrate reacts with the luminescent protein in the vicinity of the cancerous tissue to produce light which activates the photosensitizing agent resulting in the selective destruction of the cancerous tissue.
Abstract translation: 提供了一种用于光动力治疗癌细胞和组织的方法。 该方法包括向受试者施用表达发光蛋白的肿瘤营养细胞。 然后将光敏剂分别施用于受试者，随后是可选的铁螯合剂。 在治疗当天，向对象施用与发光蛋白质相应的发光底物。 底物与癌组织附近的发光蛋白反应产生激活光敏剂的光，导致癌组织的选择性破坏。
-
公开(公告)号：US20120157824A1
公开(公告)日：2012-06-21
申请号：US13393472
申请日：2010-08-31
Applicant: Stefan H. Bossmann , Deryl Troyer , Matthew T. Basel , Thilani Nishanthika Samarakoon , Hongwang Wang , Viktor Chikan , Franklin Orban Kroh , Olga Barbara Koper , Brandon Ray Walker , Xiaoxuan Leaym
Inventor： Stefan H. Bossmann , Deryl Troyer , Matthew T. Basel , Thilani Nishanthika Samarakoon , Hongwang Wang , Viktor Chikan , Franklin Orban Kroh , Olga Barbara Koper , Brandon Ray Walker , Xiaoxuan Leaym
CPC classification number: C12Q1/37 , G01N33/54346
Abstract: The present invention provides multifunctional nanoplatforms for assessing the activity of a protease in vivo or in vitro, along with methods of imaging and detecting the presence of cancerous or precancerous tissues, and the therapeutic treatment thereof, including monitoring of treatment. The diagnostic nanoplatforms comprise nanoparticles and are linked to each other or other particles via an oligopeptide linkage that comprises a consensus sequence specific for the target protease. Cleavage of the sequence by the target protease can be detected using various sensors, and the diagnostic results can be correlated with cancer prognosis. Individual unlinked nanoplatforms are also adaptable for therapeutic hyperthermia treatment of the cancerous tissue.
Abstract translation: 本发明提供用于评估体内或体外蛋白酶活性的多功能纳米平板，以及成像和检测癌或癌前组织的存在及其治疗方法，包括治疗的监测。 诊断性纳米平台包含纳米颗粒，并通过包含靶蛋白酶特异性共有序列的寡肽连接物彼此连接或其它颗粒。 可以使用各种传感器检测目标蛋白酶的序列的切割，并且诊断结果可以与癌症预后相关。 单独的未连接的纳米平台也适用于癌组织的治疗性高热治疗。
-
公开(公告)号：US20110014125A1
公开(公告)日：2011-01-20
申请号：US12920771
申请日：2009-03-03
Applicant: Stefan H. Bossmann , Deryl L. Troyer , Matthew T. Basel
Inventor： Stefan H. Bossmann , Deryl L. Troyer , Matthew T. Basel
CPC classification number: A61K49/0067 , A61K49/0036 , A61K49/0056 , A61K49/0065 , A61K49/0093 , B82Y15/00 , C07K5/1021 , C07K7/06 , C07K7/08 , C12Q1/37 , G01N33/588 , G01N2800/7028 , Y10S977/773 , Y10S977/774 , Y10S977/92
Abstract: The present invention provides a diagnostic reagent or assay for assessing the activity of a protease in vivo or in vitro and methods of detecting the presence of a cancerous or precancerous cell. The assays are comprised of two particles linked via an oligopeptide linkage that comprises a consensus sequence specific for the target protease. Cleavage of the sequence by the target protease can be detected visually or using various sensors, and the diagnostic results can be correlated with cancer prognosis.
Abstract translation: 本发明提供用于评估蛋白酶在体内或体外的活性的诊断试剂或测定法，以及检测癌性或癌前细胞的存在的方法。 测定由通过寡肽连接的两个颗粒组成，其包含对靶蛋白酶特异性的共有序列。 可以目测或使用各种传感器检测靶蛋白酶序列的切割，诊断结果可与癌症预后相关。
-
-
-
Search Results
4
records
(took 0.013 seconds)
